Table 5 Multivariable Cox analysis of potential risk factors for primary graft survival and overall patient survival in patients with retransplantation.

From: Graft-recipient-weight ratio and lowered immunosuppression is important for the success of adult liver retransplantation

Variables

n

Primary graft survival

Overall patient survival

Univariable

Univariable

Multivariable (FK included)

Multivariable (FK excluded)

HR

CI

P

HR

CI

P

HR

CI

P

HR

CI

P

GRWR

 

0.894

0.507–1.578

0.700

0.650

0.415–1.018

0.060

      

GRWR < 1.0%

6

1.607

0.377–6.855

0.521

4.243

1.758–10.241

0.001

3.668

1.150–11.698

0.028

4.065

1.676–9.861

0.002

Living donor for first transplant

75

0.994

0.446–2.218

0.989

1.016

0.552–1.871

0.958

      

Living donor for retransplant

12

1.068

0.375–3.038

0.902

1.748

0.853–3.583

0.127

      

Acute dysfunction (against chronic)

44

1.204

0.613–2.367

0.589

0.956

0.556–1.643

0.870

      

Days between transplantations ≥ 30 days

70

1.208

0.577–2.530

0.616

1.456

0.793–2.674

0.226

      

Partial graft (against whole)

15

0.814

0.286–2.318

0.700

1.700

0.874–3.305

0.118

      

MELD score

 

1.006

0.967–1.047

0.767

1.019

0.986–1.053

0.258

      

Male recipient (vs. female)

71

0.712

0.349–1.453

0.351

1.246

0.686–2.264

0.470

      

Recipient age ≥ 60 years

19

0.737

0.284–1.916

0.532

1.400

0.735–2.668

0.306

      

Hepatocellular carcinoma

37

0.796

0.387–1.635

0.534

0.981

0.568–1.693

0.944

      

Hepatic encephalopathy

22

1.334

0.602–2.957

0.478

1.728

0.939–3.182

0.079

      

Hepatorenal syndrome

50

0.944

0.473–1.884

0.870

1.107

0.643–1.908

0.714

      

Pretransplant ventilator care

22

1.551

0.720–3.341

0.262

1.974

1.099–3.548

0.023

2.004

0.904–4.442

0.087

1.723

0.900–3.298

0.101

Prehospitalization

91

2.106

0.503–8.806

0.308

1.532

0.611–3.844

0.363

      

Pretransplant inotropics

32

1.126

0.548–2.314

0.747

1.237

0.697–2.195

0.468

      

Simulect induction

58

0.601

0.286–1.263

0.179

0.990

0.557–1.760

0.973

      

Mean daily FK trough level ≥ 9 ng/mL

9

3.692

1.288–10.587

0.015

2.879

1.251–6.625

0.013

2.935

1.195–7.211

0.019

   

Mean daily MMF dosage ≥ 500 mg

34

1.009

0.454–2.240

0.983

1.002

0.555–1.807

0.996

      

Male donor (vs. female)

64

1.145

0.566–2.316

0.706

1.123

0.647–1.948

0.680

      
  1. LT Liver transplantation, reLT Liver retransplantation, RRT Renal replacement therapy, MELD Model for end-stage liver disease, GRWR Graft-recipient weight ratio.
Back to article page